Clin Pediatr Hematol Oncol.
2010 Oct;17(2):188-195.
Outcome of Patients with Localized Ewing Sarcoma Family of Tumors: Can It Be Improved with Intensified Chemotherapy?
- Affiliations
-
- 1Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea. junahlee@kcch.re.kr
- 2Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.
Abstract
- PURPOSE
The incidence of Ewing sarcoma family of tumors (ESFT) is very low in Korea. Currently, chemotherapy regimens for ESFT vary. In this study, the relationship between the dose intensity of the chemotherapy regimen and patient outcome was investigated.
METHODS
This retrospective study analyzed the data from patients with ESFT treated at the Korea Cancer Center Hospital between 1992 and 2007. Forty eight patients with localized ESFT that were treated with the chemotherapy regimen consisting ifosfamide and doxorubicin (IA) were studied and categorized into two groups: cases treated with the standard IA regimen and cases treated with an intensive IA regimen. Each group was compared with respect to clinicopathologic variables as well as survival.
RESULTS
Thirty-two patients were treated with the standard IA regimen and 16 with the intensive IA regimen. The patients treated with the standard IA were older than those treated with the intensive IA regimen (mean, 28.3 years vs. 18.3 years, P=0.02). Gender, histological subtype, tumor location, primary sites and tumor volume did not differ between the two groups. There were more good responders among patients who were treated with intensive IA regimen than in those treated with standard IA regimen (100% vs. 54.2%, P=0.01). The 5-year EFS tended to be better in those treated with intensive IA regimen (67.0+/-12.2% vs. 53.5+/-9.2%, P=0.27).
CONCLUSION
The outcome of patients with localized ESFT tended to be better with more intensified chemotherapy. The results of this study could provide the basis for a collaborative multinational study targeting ESFT.
